CAMK2G and catecholaminergic polymorphic ventricular tachycardia: The efficacy of CaMKII-suppression-based therapy was further validated in experiments using CPVT patient-derived iPSCs and CPVT mice with AAV-mediated overexpression of AIP [7, 25].